A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

ανά Sehn, Laurie H., Martelli, Maurizio, Trněný, Marek, Liu, Wenxin, Bolen, Christopher R., Knapp, Andrea, Sahin, Deniz, Sellam, Gila, Vitolo, Umberto
Τόπος έκδοσης J Hematol Oncol (2020)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma

ανά Grigg, Andrew, Dyer, Martin J.S., Díaz, Marcos González, Dreyling, Martin, Rule, Simon, Lei, Guiyuan, Knapp, Andrea, Wassner-Fritsch, Elisabeth, Marlton, Paula
Τόπος έκδοσης Haematologica (2017)

Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment f...

ανά Mir, Farheen, Mattiello, Federico, Grigg, Andrew, Herold, Michael, Hiddemann, Wolfgang, Marcus, Robert, Seymour, John F., Bolen, Christopher R., Knapp, Andrea, Nielsen, Tina, Casulo, Carla
Τόπος έκδοσης Am J Hematol (2020)

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma

ανά Davies, Andrew, Trask, Peter, Demeter, Judit, Florschütz, Axel, Hänel, Mathias, Kinoshita, Tomohiro, Pettengell, Ruth, Quach, Hang, Robinson, Stephen, Sadullah, Shalal, Sancho, Juan-Manuel, Udvardy, Miklos, Witzens-Harig, Mathias, Knapp, Andrea, Liu, Wenxin
Τόπος έκδοσης Ann Hematol (2020)

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

ανά Kostakoglu, Lale, Martelli, Maurizio, Sehn, Laurie H., Belada, David, Carella, Angelo-Michele, Chua, Neil, Gonzalez-Barca, Eva, Hong, Xiaonan, Pinto, Antonio, Shi, Yuankai, Tatsumi, Yoichi, Knapp, Andrea, Mattiello, Federico, Nielsen, Tina, Sahin, Deniz, Sellam, Gila, Oestergaard, Mikkel Z., Vitolo, Umberto, Trněný, Marek
Τόπος έκδοσης Blood Adv (2021)